Johnson & Johnson $JNJ Shares Bought by Clough Capital Partners L P

Key Points

• Clough Capital Partners L P increased its stake in Johnson & Johnson by 164.3% in Q1, owning 7,401 shares valued at $1,227,000.
• Several analysts have adjusted their price targets for Johnson & Johnson, with Citigroup raising it to $200.00 while Morgan Stanley set it at $176.00, and the average consensus price target stands at $176.29.
• Johnson & Johnson reported Q2 earnings of $2.77 EPS, exceeding estimates, with a quarterly revenue of $23.74 billion reflecting a 5.8% year-over-year increase.

Clough Capital Partners L P grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 164.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,401 shares of the company's stock after acquiring an additional 4,601 shares during the period. Clough Capital Partners L P's holdings in Johnson & Johnson were worth $1,227,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of JNJ. Lantz Financial LLC grew its holdings in Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after purchasing an additional 377 shares during the period. Sulzberger Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at $453,000. Apexium Financial LP increased its holdings in Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after acquiring an additional 2,310 shares in the last quarter. Joel Isaacson & Co. LLC raised its position in Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after acquiring an additional 2,526 shares during the period. Finally, State of Wyoming lifted its holdings in Johnson & Johnson by 205,580.0% during the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after purchasing an additional 10,279 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Citigroup lifted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research note on Thursday, August 21st. Barclays increased their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $175.50 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a 50 day moving average price of $165.45 and a 200 day moving average price of $159.86. The stock has a market cap of $422.67 billion, a PE ratio of 18.77, a P/E/G ratio of 2.25 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the firm posted $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.